Adjuvant Nivolumab/Ipilimumab Falls Short of RFS End Point in Resected, Late-Stage Melanoma
Source: OncLive, April 2021
The addition of ipilimumab (Yervoy) to nivolumab (Opdivo) as an adjuvant treatment failed to improve relapse-free survival (RFS) in the intent-to-treat (ITT) and PD-L1 of less than 1% populations compared with nivolumab alone in patients with resected stage IIIB to D/IV melanoma, missing the dual primary endpoints of the phase 3 CheckMate-915 trial (NCT03068455) that were presented during the virtual AACR Annual Meeting 2021.1
